Everything below concerns storage stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
== Career == Akagha attended Southern Methodist University in Dallas, Texas, where she majored in theatre. In the early 2010s, she acted in theatrical productions in California. In 2010, she played Tiger Lily in the Pacific Conservatory of the Performing Arts's production of Peter Pan. In 2011, she acted alongside Brendan Cataldo in Leo Cortez's play, Acting Out, at the Alisal Center for the Fine Arts. In 2012, Akagha began playing the leads in various short films and making guest appearances in television series. She appeared in one-off episodes in the series Men at Work, Nashville and 2 Broke Girls. Akagha started voice acting in video games around 2016, first voicing the character "Plastic" in the game Mirror's Edge: Catalyst. In 2017, she was a voice actor for Wolfenstein II: The New Colossus, in which she provided voices for characters Barbara Casey, Zena Woodard, and Angela Cummings. In 2018, she began appearing in Marvel's Runaways television series as Tamar, a recurring, supporting role. She provided the voice for the superheroine Bumblebee in the animated series Teen Titans Go!. Bumblebee initially appeared in the show's fifth season in the episode "Forest Pirates", which aired in 2019. Akagha voiced the main character, Alyx Vance, in the virtual reality game Half-Life: Alyx. The character was first introduced in the game Half-Life 2 in 2004, being originally played by Merle Dandridge. A new actor was chosen for Alyx Vance partially due to the character's younger age and the "time gap" between this and the previous game.
Binding of PPARγ to coactivators appears to reduce the levels of coactivators available for binding to pro-inflammatory transcription factors such as NF-κB; this causes a decrease in transcription of a number of pro inflammatory genes, including various interleukins and tumour necrosis factors.
== OSCE monitors == A former senior Organization for Security and Co-operation in Europe (OSCE) official, Ryan Grist, who was responsible for monitors in South Ossetia at war's start, told the BBC in November 2008 that he had been warning of Georgian military movement before the full-scale war, saying there was a "severe escalation" and that this "would give the Russian Federation any excuse it needed in terms of trying to support its own troops." According to Grist, the first attack on Tskhinvali came from Georgia, which "was completely indiscriminate and disproportionate to any, if indeed there had been any, provocation." Grist's views were echoed by Stephen Young, who was another senior OSCE official in Georgia at the time. According to him, there had been no large-scale shelling of the Georgian villages on late 7 August. Young added, that if Georgian villages had been shelled heavily that evening, the OSCE monitors at the scene would have heard it. According to him, "only occasional small arms fire" was heard. Georgian officials and some Western diplomats in Tbilisi later disputed Grist's neutrality. The attempts by The New York Times to interview the monitors were curbed by the OSCE. The OSCE sought to avoid open involvement in dispute. The monitors' claims were assessed as "a bit irrelevant" by head of the OSCE mission to Georgia Terhi Hakala.
Sources: en.wikipedia.org
=== Regulation in Britain and the United States === Before the 1920s, regulation in Britain was controlled by pharmacists. Pharmacists who were found to have prescribed opium for illegitimate uses and anyone found to have sold opium without proper qualifications would be prosecuted. With the passing of the Rolleston Act in Britain in 1926, doctors were allowed to prescribe opiates such as morphine and heroin if they believed their patients demonstrated a medical need. Because addiction was viewed as a medical problem rather than an indulgence, doctors were permitted to allow patients to wean themselves off opiates rather than cutting off any opiate use altogether. The passing of the Rolleston Act put the control of opium use in the hands of medical doctors instead of pharmacists. Later in the 20th century, addiction to opiates, especially heroin in young people, continued to rise and so the sale and prescription of opiates was limited to doctors in treatment centres. If these doctors were found to be prescribing opiates without just cause, then they could lose their licence to practice or prescribe drugs. Abuse of opium in the United States began in the late 19th century and was largely associated with Chinese immigrants. During this time the use of opium had little stigma; the drug was used freely until 1882 when a law was passed to confine opium smoking to specific dens. Until the full ban on opium-based products came into effect just after the beginning of the twentieth century, physicians in the US considered opium a miracle drug that could help with many ailments.
=== April === 1 April – Former Conservative government minister Sir Alister Jack, who admitted placing three bets on the outcome of the 2024 United Kingdom general election, is to be appointed to the House of Lords. Stephen Flynn, the Scottish National Party's leader at Westminster, confirms his intention to stand for the party in the 2026 Holyrood election. 2 April – Patrick Harvie announces he is standing down as co-leader of the Scottish Greens, but will stay on until an election is held in the summer. 3 April – The Labour Party campaign for the local elections is launched in Derbyshire. 4 April – Jamie Greene, an MSP who left the Scottish Conservatives the previous day, joins the Scottish Liberal Democrats, blaming his decision to leave the Conservative on them becoming "Trump-esque in both style and substance" in an attempt to win the support of right-wing voters. He subsequently says there is "growing disquiet" among former colleagues about the party's direction. Stephen Hartley, a Reform UK candidate for the local elections to Oxfordshire County Council, is suspended from the party after it was revealed he had posted comments in support of child abuser Jimmy Savile on social media. 5 April – Labour suspends Dan Norris, the MP for North East Somerset and Hanham, following his arrest on suspicion of rape, child sex offences, child abduction and misconduct in a public office. 6 April – Labour MPs Abtisam Mohamed and Yuan Yang say they are "astounded" to have been refused entry to Israel while on a trip to visit the West Bank.
=== Industry sectors === Singapore is the world's third-largest foreign exchange centre, sixth-largest financial centre, second-largest casino gambling market, third-largest oil-refining and trading centre, largest oil-rig producer and hub for ship repair services, and largest logistics hub. The economy is diversified, with its top contributors being financial services, manufacturing, and oil-refining. Its main exports are refined petroleum, integrated circuits, and computers, which constituted 27% of the country's GDP in 2010. Other significant sectors include electronics, chemicals, mechanical engineering, and biomedical sciences. Singapore was ranked 5th in the Global Innovation Index in 2025. In 2019, there were more than 60 semiconductor companies in Singapore, which together constituted 11% of the global market share. The semiconductor industry alone contributes around 7% of Singapore's GDP. Singapore's largest companies are in the telecommunications, banking, transportation, and manufacturing sectors, many of which started as state-run statutory corporations and have since been publicly listed on the Singapore Exchange. Such companies include Singapore Telecommunications (Singtel), Singapore Technologies Engineering, Keppel Corporation, Oversea-Chinese Banking Corporation (OCBC), Development Bank of Singapore (DBS), and United Overseas Bank (UOB). In 2011, after the 2008 financial crisis, OCBC, DBS and UOB were ranked by Bloomberg Businessweek as the world's first, fifth, and sixth strongest banks in the world, respectively.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.